Dasatinib induces a response in chronic lymphocytic leukemia

To the editor: Dasatinib is a novel oral multitargeted kinase inhibitor of Bcr-Abl and Src family widely used for the treatment of imatinib-resistant chronic myelogenous leukemia. Furthermore, preclinical studies by Shah et al[1][1] indicate that dasatinib may also inhibit gastrointestinal stromal